Research and development investment of Chinese chemical pharmaceutical companies under the national pooled procurement: a retrospective panel data analysis, 2013–2022
Objective To generate evidence about changes in the research and development (R&D) investment of Chinese chemical pharmaceutical companies before and after the implementation of the national pooled procurement, to respond to the concerns that significant price reductions might negatively aff...
Saved in:
| Main Authors: | Yuanli Liu, Jing Sun, Qianrun Lei, Qiyou Wu, Zhitao Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/11/e081503.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Investment analysis and risk management in pharmaceutical companies
by: Mustafa Özyeşil, et al.
Published: (2025-05-01) -
Foreign investment activities of Chinese companies
by: Antevski Miroslav, et al.
Published: (2014-01-01) -
R&D investment and total factor productivity in China’s pharmaceutical industry: The moderating effect of the centralized procurement policy
by: Xiujuan Li, et al.
Published: (2025-01-01) -
Assessing perceptions of establishing a vaccine pooled procurement mechanism for the Western Pacific Region.
by: Alice Abou-Nader, et al.
Published: (2022-01-01) -
Greenwashing and investment attractiveness of companies for «green» investments to the national economy
by: I.O., et al.
Published: (2022-08-01)